A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study
Year: 2014
Type: article
Study design: Clinical Trial
Source: Gynecologic Oncology
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, University of Washington Medical Center, University of California, Irvine, University of Pennsylvania, Yale University, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4235134136